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The Heart Failure Association of the European Society of Cardiology has published a previous position paper and various guidelines over
the past decade recognizing the value of palliative care for those affected by this burdensome condition. Integrating palliative care into
evidence-based heart failure management remains challenging for many professionals, as it includes the identification of palliative care needs,
symptom control, adjustment of drug and device therapy, advance care planning, family and informal caregiver support, and trying to ensure
a ‘good death’. This new position paper aims to provide day-to-day practical clinical guidance on these topics, supporting the coordinated
provision of palliation strategies as goals of care fluctuate along the heart failure disease trajectory. The specific components of palliative
care for symptom alleviation, spiritual and psychosocial support, and the appropriate modification of guideline-directed treatment protocols,
including drug deprescription and device deactivation, are described for the chronic, crisis and terminal phases of heart failure.
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Introduction
Over the last 30 years, the 5-year survival rate for patients with
heart failure (HF) has improved by approximately 30% across all
healthcare settings, predominantly related to advances in treatment
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. for HF patients with a reduced ejection fraction (HFrEF).1 At
present, there are no particularly effective treatment modalities
for those exhibiting HF with a preserved ejection fraction (HFpEF),
care being directed towards management of their symptoms and
comorbid/antecedent conditions. Better survivorship is manifest
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in more elderly patients living longer with chronic HF,2 a condition
with a fluctuating and unpredictable disease trajectory associated
with a severe symptom burden and poor quality of life.
Clinical guidelines and consensus papers advise the con-
current provision of palliative and supportive care alongside
life-prolonging therapies in HF management.3–5 Palliative care as
defined by the World Health Organization, is an approach that
improves the quality of life of patients and families through the
prevention and relief of suffering,6 focusing on expert assess-
ment and management of symptoms, evaluation and support
of informal caregivers, and the interdisciplinary coordination of
continuing care.
Since the first position statement on palliative care by the Heart
Failure Association (HFA) of the European Society of Cardiology
(ESC) in 2009,4 palliative care in HF has been addressed in numer-
ous conferences and workshops, the subject area supported by a
growing body of research.7 Nevertheless, according to the HFA
atlas, only 10 out of 42 European countries have designated pallia-
tive care units for patients with advanced HF, with the European
Association of Palliative Care describing 8 countries as providing
fully integrated palliative and cardiology services.8,9 Whilst many
professionals recognize the importance of palliative care as part
of everyday HF management, not all patients receive this support.
Potential barriers include the intrinsic uncertainty of the HF trajec-
tory, a lack of organizational resources, staff training and available
time, and healthcare professionals (HCPs) perceiving palliative care
as being of low priority.10–12 In addition, there may be psychosocial,
ethical and legal issues, sometimes involving patient and informal
caregiver expectations, or related to deprescribing, anticipatory
prescribing, deactivation of implanted devices, and the enactment
of advanced directives and resuscitation policies.13,14 Acknowl-
edging the worldwide diversity in legislation, cultural norms, pro-
fessional education, role perception and resource availability, this
paper offers day-to-day guidance for HCPs managing patients with
HF. Furthermore, informed by insightful contributions from ESC
Patient Forum representatives, it prioritizes features relevant to
patients as service users. The overall aim of this document is to
synthesize the available evidence and provide clinical guidance on
integrating palliative and HF care. We highlight gaps in knowledge,
and signpost areas for future research.
When and how to address
palliative needs
Many patients with HF would derive benefit from the early inte-
gration of a palliative approach within the care provided by all
members of the HF multidisciplinary team (MDT), recognizing this
supportive intervention complements optimal guideline-directed
therapies (Figure 1). However, often the attention of HCPs is drawn
to prognostic indicators rather than undertaking a comprehensive
assessment of patients’ needs.15,16 Patient-reported outcome mea-
sures (PROMs) are useful in collating multidimensional symptoms,
a number of tools being used internationally within clinical prac-
tice and HF research.17,18 However, such evaluation tends to be



















































































.. validated instruments applicable to patients admitted with acute HF
or cardiogenic shock for whom treatment outcomes remain par-
ticularly uncertain.19 Cultural and religious beliefs should also be
characterized and considered within this support matrix to bet-
ter ensure responsive healthcare practice is coherent with each
patient’s unique sociocultural worldview.20–22
How to identify the need for a palliative
approach?
Tools for patient-reported symptoms (online supplementary
Table S123–36) may assist in identifying the need for a palliative
approach. In addition, persistent severe impairment of quality of
life, escalating symptoms and mood disturbance, may be regarded
as indicators for assessment by a palliative care specialist.30,37 The
‘I need help’ acronym38 includes key features helpful in identifying
those who may be worthy of palliative care, in accordance with
American and ESC guideline criteria and consensus statements.39,40
Several prognostic risk calculators are available and have
been critically reviewed,16,41,42 although prognostication on an
individual basis remains challenging. Clinical markers useful as
prognostic indicators include the presence of right ventricular
systolic and diastolic dysfunction,43,44 persistent elevation of
natriuretic peptide and cardiac troponin levels,45,46 and elevated
pulmonary capillary wedge and right atrial pressures.47 Worth-
while prognostic information, easily accessible in everyday practice,
includes advanced age, progressive worsening of renal function,
intolerance of disease-modifying agents,42,48,49 the presence of
chronic obstructive pulmonary disease or diabetes, persisting
hypotension, a markedly reduced ejection fraction, symptomatic
classification as New York Heart Association (NYHA) III–IV,42,48
anaemia and/or iron deficiency,48,49 and an anorexia–cachexia
syndrome.42,50
What are the roles of families
and informal caregivers?
Families and informal caregivers are crucial partners in the HF
care team, their support influencing patients’ self-care and mental
well-being, as well as prognosis, their involvement often changing
and intensifying during clinical crises and the terminal phase51
(Figure 1). At the time of diagnosis, informal caregivers and
family members may have to deal with emotional distress and
a disruption of ‘normal’ life as they help the patient cope with
loss of independence, social isolation, increasingly burdensome
symptoms, and an awareness that death might be imminent.52 They
may often feel ‘hopeless or powerless’, with hospitalization events
and post-discharge transitions from hospital to home particularly
stressful periods.53 In advanced disease, caregivers are often called
upon to navigate the healthcare system, contribute to decisions
regarding complex treatment options and deal with complicated
pharmacological treatment regimens and devices. The HF Care-
giver Questionnaire (HF-CQ) is a validated instrument, which
may be used to assess caregiver burden and prompt appropriate
support.54
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Figure 1 Integrating palliative care throughout the heart failure (HF) trajectory.
What is advance care planning?
Advance care planning (ACP) is synonymous with anticipatory
care planning and advance directives. These may include a living
will, which in some jurisdictions is a legally binding document.55
Irrespective of age, nearly half of all patients with HF have some
degree of cognitive impairment,56 emphasizing the need for early
ACP and palliative care discussions. In addition, as the prevalence
of dementia correlates with increased age,57 there is a widespread
recognition of the need for dementia-specific palliative care
strategies.58
For many patients, the issues addressed within ACP tend to be
limited to treatment choices if capacity is lost when close to death,
often focused on cardiopulmonary resuscitation policies, the use
of mechanical ventilation or artificial hydration/nutrition,59 or
when a decision is required on the deactivation of an implantable
cardioverter-defibrillator (ICD). Consideration for therapy with-
drawal needs to take into account the patient’s physiological status,
overall quality of life, cultural and spiritual beliefs, current or pre-
viously declared treatment preferences, setting these elements































. reduced readmission rates, increased involvement in palliative care
services, and through shared decision making with the patient and
family, an increased probability of fulfilling their preferences for
the place of care and death.60–62
This paper takes a neutral stance and does not offer guidance
on assisted suicide or euthanasia. However, it should be noted that
both assisted suicide and/or active euthanasia are legal in some
European countries.
How to effectively manage
distressing symptoms
Over recent years the mode of death for HF patients has
changed, fewer succumbing to sudden death.63,64 However, more
than half still die from a cardiovascular cause.65 Many of these
patients have interlinking comorbidities, therefore their final few
months of life may be characterized by distressing, debilitating and
refractory symptoms, arising from both cardiac and non-cardiac
conditions, including cancer (Table 1).24,66–92 Patients are also
subject to the practical, psychological and social consequences
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Breathlessness






IPOS, Borg or Likert scales.




Non-pharmacology: Sitting upright, hand-held fans, relaxation
techniques, breathing exercises
Pharmacology: Optimal HF medical therapy. Consider
benzodiazepines for anxiety and opiates (morphine).
Little benefit of supplementary oxygen in advanced HF
alone66,67
Fluid retention





Physical exam including weight




pressure measurement devices, e.g.
OPTiVOL/ CardioMEMS
Portable lung ultrasound (V scan)
Non-pharmacology: Support stockings/leg elevation.
Long-term in-dwelling drains, e.g. PleurX™ for chronic
pleural effusions and ascites
Pharmacology: Diuretic therapy – intravenous or
subcutaneous within home or hospice. Tolvaptan for
severe congestion and hyponatraemia.
Calcium-sensitizing inodilator, levosimendan could be
considered intermittently in the ambulatory setting68–72
Thirst










Non-pharmacology: Free fluids, artificial saliva, sucking ice
chips, peppermint or buttermilk candies, chewing gum








Non-pharmacology: Frequent oral hygiene, candies and suck
ice cubes
Pharmacology: Artificial saliva as gel, topical spray, rinse,
dissolving tablets24,75
Pain








Brief Pain Inventory (BPI)
Non-pharmacology: Acupuncture, physical therapy,
mindfulness-based stress reduction, exercise and music
Pharmacology: Neuropathic pain can be treated with
non-opioid medications (anticonvulsants,
antidepressants) and opioids. Tramadol, oxycodone,










Function Index for Women
Non-pharmacology: Exercise, smoking cessation
Pharmacology: Medication replacement if needed, e.g.
change of beta-blocker, use of PDE-5 inhibitors
(sildenafil, tadalafil, vardenafil). Caution with combining
with nitrates.
Women—advise topical vaginal oestrogen preparation79–81
Nausea and vomiting








Non-pharmacology: Removal/replacement of offending
medications. Try individual dietary changes, avoid
triggering smells, alternative or complementary medicine
Pharmacology: Metoclopramide (caution as may prolong
QT), promethazine, prochlorperazine, ondansetron,








Non-pharmacology: Physical activity, dietary changes
Pharmacology: Laxative, stool softeners, methylnaltrexone











Dutch Fatigue Scale (DUFS)






Pharmacology: Adjust drug dosage (diuretics, beta-blockers),
address comorbidities (iron supplementation)83,84
Depression/anxiety






Poor spiritual well-being PHQ-9
HADS






Non-pharmacology: Open communication, cardiac
rehabilitation, exercise and psychological therapies, e.g.
CBT
Pharmacology: SSRIs safe and relatively well tolerated in HF
but limited evidence of efficacy85–92
BDI-TDI, Baseline Dyspnoea Index-Transitional Dyspnoea Index; CBT, cognitive-behavioural therapy; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CTEPH, chronic
thromboembolic pulmonary hypertension; DM, diabetes mellitus; ESAS, Edmonton Symptom Assessment Scale; HADS, Hospital Anxiety and Depression Scale; HF, heart failure; IIEF, International Index of
Erectile Function; ILD, interstitial lung disease; IPOS, Integrated Palliative Care Outcome Scale; NRS, Numerical Rating Scale; NYHA, New York Heart Association; PDE, phosphodiesterase; PHQ, Patient
Health Questionnaire; QEQ, Quality of Erection Questionnaire; SHIM, Sexual Health Inventory for Men; SSRI, selective serotonin reuptake inhibitor; VAS, visual analogue scale.
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of living with a chronic progressive disease, or the side effects of
medications.63,85,93 Symptoms can cluster, and whilst they can be
mitigated to some extent, toward the end of life, they can seem
overwhelming. For patients hospitalized due to decompensated
HF symptoms, inotropic therapy may be considered3 with lev-
osimendan proposed as appropriate for patients on beta-blocker
therapy.68 For the HF cohort, robust evidence for many symptom
control interventions are lacking, but this should not deter from
pursuing on a trial basis.
Early intervention is required to maintain optimal physical func-
tioning and psychological well-being as many patients with HF have
reduced exercise tolerance and fatigue, which can detrimentally
impact prognosis and quality of life.94,95 To achieve optimum clinical
benefit from exercise, patients’ hydration status, electrolytes and
dietary intake including supplements should be actively managed.
Exercise-based cardiac rehabilitation is recommended for patients
with relatively stable chronic HF (NYHA I–III).96,97 During a clin-
ical crisis phase (Figure 1), patients’ tolerance of physical activity
becomes extremely limited. Furthermore, for patients in the ter-
minal phase of life, it is advised that physical therapy be restricted
to maintaining a sense of balance, with passive limb exercises to
prevent contractions. Involvement of a physiotherapist may be ben-
eficial. (online supplementary Table S2 outlines HF phases and cor-
responding exercise prescription96–98).
Frailty, cachexia and sarcopenia
Frailty, cachexia and sarcopenia are associated with the advanced
stages of HF. Frailty, exhibited in a poor physiological reserve
and increased vulnerability, is considered to be prevalent in about
45% of HF patients. However, the proportion affected is uncertain
as no assessment tool has been specifically validated for the HF
population.99,100 Cachexia and/or sarcopenia may be evident in
5–15% of patients with either HFrEF or HFpEF.101 Recognition
varies within clinical practice, the first indicator often being a
>5% involuntary non-oedematous weight loss over a period of
3–12 months. If diagnosed early, frailty, cachexia and sarcopenia
may be attenuated through exercise and dietary interventions
provided alongside optimal guideline-directed HF therapy.99,102,103
Communication with patients,
families, and informal caregivers
As demonstrated in Figure 1, the turbulent nature of the HF tra-
jectory requires HCPs to revisit earlier decisions on therapy with
their patients, recalibrating goals of care to ensure treatment poli-
cies remain appropriate to the phase of the condition. If the dis-
ease progresses inexorably, previously expected outcomes may
have become unrealistic and now represent false hopes.104 Sen-
sitive conversations demand protected space and good commu-
nication skills to avoid increasing patients’ and family members’
anxiety, undermining care plans and adversely impacting patient
outcomes.105 To ensure continuity and prevent misunderstand-
ing, discussions and decisions should be fully documented, regu-



















































































.. patient’s care. Although there is no standard formula for good com-
munication, the following steps may be helpful (Table 2).
Despite a relatively light literature base, useful insights into effec-
tive approaches to end of life communication have been collated
and reviewed.106,107 Professionals appear to benefit from formal
communication skills training, particularly focusing on breaking bad
news. Question prompt lists (QPL) are tools that can generate
useful discussion during consultations and are readily accessible
and easily adopted into routine practice. An example of a QPL
designed for HF patients has been pilot tested.108 Basic considera-
tions when advising patients and informal caregivers are provided
(online supplementary Table S3).
Managing treatment expectations
Many patients with advanced HF maintain a sense of optimism,
valuing quality but hoping through the provision of evidence-based
drug, device or surgical options, that their lives will also be
prolonged.1,5,109 Beliefs and hope for a positive outcome vary
across international borders and cultures,110 and can be attributed
to past experiences, unrealistic expectations of treatment benefits,
and the availability of advanced technology and local expertise.111
Some patients may demonstrate a ‘protective denial’ of their
poor prognosis, indicating they are not psychologically attuned to
acknowledge the progressive nature of their disease or discuss end
of life care.112 The continued pursuit of disease-modifying therapy
should be balanced and integrated with a palliative approach.113,114
Due to the ambiguous disease trajectory, professionals may feel
justifiably uncertain about an individual’s prognosis, and uncom-
fortable initiating difficult conversations early in the course of the
disease.115–117 However, deferment runs the risk of information
exchange being ‘too little and too late’.118
Bereavement care
Bereavement is a universal experience, defined as the ‘situation of
having recently lost a significant person through death’. Bereaved
individuals may experience a range of debilitating physical and
psychological responses,119 and these should be addressed by an
assigned member of the MDT. For some, having experienced the
significant suffering of a relative or friend, death may be viewed
as a release. For others, bereavement is deep and protracted, and
is characterized as complicated grief,120 perhaps not unexpected
in those exposed to the sudden cardiac death of a loved one.
Involvement of specialist palliative care may significantly support
affected individuals.
How to provide palliative care
All professionals within the HF MDT are equipped, to some extent,
in identifying clinical decline, initiating appropriate discussions, alle-
viating burdensome symptoms, negotiating supportive resources
within the healthcare system, and providing some elements of pal-
liative care.66,121,122 While the current empirical evidence base for
the delivery of palliative care by HF professionals is limited, this
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Communication strategies
Initiating discussion: This includes establishing a rapport and supportive relationship with the patient and family, as the healthcare professional
explores their general thoughts about preferences and expectations for treatment and care.
Example:
‘While I cannot cure your heart failure there are still many things that I can do for you. I want you to be able to speak openly with me, so I can best help
you. No matter what happens, I can be here for you — you are not alone’
Clarifying prognosis: Be direct, yet caring, be truthful, but sustain hope, use simple everyday language.
Example:
‘Most people with heart failure at your stage of the disease, continue to live well, but I cannot predict exactly for how long you will live. I certainly hope that
you will do better than average, but you may do worse’
Identifying goals: Facilitate open discussion about desired treatment and care and targets to be achieved however small.
Example:
‘I want to make sure we are always doing the things that might help you, and that we never do anything that either do not help you, or you would not want.
So, I need to know what things are most important to you, given your illness. What things do you still wish to do?’
Developing a treatment plan: This includes providing guidance to promote understanding of treatment and care options, making
recommendations regarding their appropriateness, clarifying resuscitation orders and possible deactivation of devices, initiating further
support, when indicated, and discussing how to act in case of a medical emergency.
Example:
‘We have talked about your illness and your poor prognosis. You have told me about how you want to spend your final months. I also need to know your
thoughts about the use of cardiopulmonary resuscitation’
Table 3 Possible triggers for the involvement of
specialist palliative care for those with heart failure
Refractory or complex symptoms
When there is spiritual or existential distress
Recurrent HF admissions
Increasingly frequent appropriate ICD shocks
When considering ICD deactivation or non-replacement
Before LVAD implantation or transplant referral
When initiating palliative inotropic therapy
Declining functional status due to progressive HF or a comorbidity
If patients and/or informal carers/surrogates disagree on goals of
care
If there is a request for assisted suicide
HF, heart failure; ICD, implantable cardioverter-defibrillator; LVAD, left ventric-
ular assist device.
approach has also been proposed as a sustainable model, supported
by evidence that upskilling of specialist HF nurses reduces referral
rates to specialist palliative care services.123,124 However, patients
close to the end of life, may require specialist palliative care involve-
ment. Table 3 provides some possible prompts when this should be
considered.
Current models have a ‘shared care’ or collaborative approach,
concentrating on the relief of physical, psychological, social and/or
existential burdens, and improving quality of life and spiritual
well-being.23,30,114 These are centred on MDT involvement with
input from allied professionals, depending on individual patients’
needs. The process of integrating palliative care into HF man-
agement will be determined by national healthcare structures
and local service configuration.30,125,126 To date, no dominant
paradigm of HF palliative care has emerged, but several service
models have been developed showing positive outcomes in deal-



















































. decompensated chronic HF,34,127,128 those transitioning to care
in the community post discharge,129,130 and home-based services
directed at community-dwelling people living with chronic HF.23
The responsibilities of the team members within such MDTs
should be defined, and it may be helpful to nominate a HCP to act
as interlocutor between the patient/informal caregiver and service
provider. For patients treated in independent hospices, it is impor-
tant to ensure the availability of HF medication, and unrestricted
access to the means and expertise of deactivating devices such
as ICDs.131,132
How to deal with devices
The possible withdrawal of cardiovascular implantable electronic
devices, either as standalone ICDs or those combined with cardiac
resynchronization therapy (CRT-D), should be sensitively broached
within a valid informed consent process pre-implantation,133,134
with further and more detailed discussions at regular intervals.
However, patients, family members and HCPs often avoid this
uncomfortable discourse, with the discussion dependent on
patient and professional factors, such as triggered by the experi-
ence of a shock.117,135 Many reports document that ICD activity is
often maintained in patients imminently dying136 despite guidelines
having been formulated to facilitate ethically appropriate ICD
deactivation.137 It is important that local protocols are in place
to ensure the timely availability of equipment and adequately
trained staff to facilitate both emergency suspension of defibril-
lator function by means of a magnet, and definitive deactivation
by reprogramming, across all patient care settings, inclusive of
community-based palliative care and primary care services. For
CRT-D patients, only the shock function should be suspended,
as interruption of CRT may increase symptom burden, a risk
also inherent in the rarely indicated withdrawal of a permanent
pacemaker implanted for bradycardia. Even after death, device
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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deactivation is still necessary to prevent a shock risk to pathology
or mortuary staff, and both ICDs and pacemakers require to be
explanted prior to cremation.138
In recent years, mechanical circulatory support (MCS) has
emerged, notably in the form of left ventricular assist devices
(LVADs), implanted as a bridge to decision making or recovery, a
bridge to transplantation, or as destination therapy (DT-LVAD).139
Some patients are offered ‘preparedness planning’ prior to implan-
tation of MCS, with exploration of their short- and long-term pref-
erences for care,140 synergizing the complementary skill sets of pri-
mary care, cardiology and specialist palliative professionals.141,142
For DT-LVAD patients, the most common modes of death are
multi-organ failure, stroke, or progressive HF,143 the terminal phase
often occurring in a hospital intensive care unit. In the face of major
complications, planned discontinuation of LVAD therapy might be
indicated, death usually occurring within an hour of withdrawal.144
Brush et al.145 have drawn up a flow-chart illustrating one approach
to end of life care for patients with DT-LVADs, and a number of
decision aids and informational tools may assist patients and families
facing such dilemmas.146,147
Palliative care support should also be offered to those individuals
who are deemed to be device ineligible or choose to forgo
primary device implantation or replacement. Similar support is also
applicable to those turned down for transcatheter aortic valve
implantation,148 or MitraClipTM (Abbott Cardiovascular Systems,
Abbott Park, IL, USA) for severe functional mitral regurgitation,
the benefits of which are currently uncertain in the general HF
population.149–151
How to ensure a good death
Whilst much of the ‘good death’ template has been founded on the
cancer model, transferability to HF care is worthwhile, particularly
within an elderly care setting.152 General principles of what charac-
terizes a ‘good death’ have been developed (online supplementary
Table S4).153–155 First and foremost is the need to recognize that
the patient has reached their final days of life.156,157 An important
and difficult aspect to discuss is the care setting in which patients
wish to receive terminal care and ultimately die.158 It is well rec-
ognized that hospice care is underused by patients with HF, mainly
accommodating people with cancer.9,12,63 Achievement of the pre-
ferred place of death is accepted as a quality indicator of good
end of life care, which can be facilitated through involvement of
palliative care.159,160 Most people prefer to die in their comfort
zone at home, where they have a sense of control, familiarity,
and are in the presence of family. Yet for some older adults, such
home deaths are more difficult to achieve, requiring adaptations
to facilitate a ‘hospital at home’ arrangement. Care at home can
often entail reduced input from specialist services, with increased
reliance on primary care physicians and community-based nurses.
In cases of poor pain control or the need for an enhanced level
of care beyond the capabilities of informal caregivers and primary
care team, patients might opt to die in an institution.159,160 How-




















































































Table 4 Medications used for anticipatory prescribing
Situation Prescribe
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Shortness of breath Opioids (morphine, oxycodone)
Pain Paracetamol, opioids (morphine,
oxycodone)
Nausea/vomiting Metoclopramide, ondansetron







Sore wounds level 1–2 Dressings and preparations
All medications should include oral/intravenous/subcutaneous routes of admin-
istration where possible.
often preceded by multiple admissions featuring aggressive treat-
ment protocols, disrupting care continuity, impacting the quality of
remaining life, and ultimately a good death.158
People close to the end of life should still expect to receive
good care, this presumption founded on trust, confidence and
hope, all of which may be tempered by their past and current
subjective experiences of interacting with HCPs or the local
healthcare system.161 Moreover, the reality and process of ‘dying’
is intensely personal, requiring time for people to deal with any




Maintaining patient and family autonomy, preparing them for
unpredictable situations and providing the necessary means for
self-care are essential elements for successful care at home. One
approach to promote this lies in ‘anticipatory prescribing’, namely
writing prescriptions for medications that might be needed as a
matter of urgency in the near/intermediate future. Having such
medications (Table 4) readily accessible at home with detailed
instructions for their use, can empower patients and caregivers in
self-management until professional supervision is available. If the
patient is at home, responsibility for such prescriptions may be with
primary care physicians, HF specialist nurses or community-based
nurse managers, in accordance with local governance arrange-
ments. For patients in a hospital or hospice setting, the cardiologist
or palliative care physician may undertake this responsibility. It
is important that decisions are synchronized through the MDT
process, offering access to a breadth of clinical expertise. For
example, the sensation of dyspnoea is often clustered with anxiety.
Opiates can be used for breathlessness, and benzodiazepines may
be considered as an anxiolytic. However, even the short-term use
of benzodiazepines can cause somnolence and increase the risk of
falls, particularly in the elderly.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Medication deprescribing is a proactive, patient-centred
approach, founded on a seamless revision of good prescribing prin-
ciples, taking into consideration the context of patients changing
goals of care, values, preferences and perceived life expectancy.163
Most scientific literature on drug discontinuation stems from
the field of cancer and geriatric palliative care.164 There are a
variety of reasons to deprescribe in the setting of inexorable HF
progression: where treatment burden outweighs benefit, the risk
of adverse drug reactions increases with polypharmacy, declining
pharmacologic and metabolic efficacy, and poor patient adherence.
Professionals may be reticent or experience resistance to the
withdrawal of established and sometimes long prescribed drug
therapies. Some prescriptions worthy of possible withdrawal
include medications no longer conferring symptomatic benefit
such as statins or antiplatelet therapies. Optimizing diuretic
therapy and down-titrating beta-blockers may be considered
in the face of worsening congestion. Similarly, symptomatic
hypotension may require down-titration of both beta-blockers and
renin–angiotensin–aldosterone system inhibitors.
During the deprescription process, professionals need to moti-
vate change by engaging with and supporting patients and families. A
potentially useful electronic resource on medication deprescribing
is available, and may provide confidence and reassurance.165
Who takes cares of the healthcare
professional?
Healthcare professionals regularly handling life and death situations
are particularly exposed to both clinical and ethical dilemmas which
undermine their resilience, putting them at risk of moral distress
and burnout. Emotional exhaustion, depersonalization and detach-
ment can lead to declining empathy, with a lack of compassion
hampering clinician–patient relationships and the quality of care
delivery.166,167 Whilst these issues are more common in intensive
care unit staff, HCPs involved with HF patients are not immune
to such responses. Debriefing, mindfulness, and reflective practice
can support the spirit and stamina of HF professionals.168,169 Addi-
tional options include the availability of safe spaces within MDTs,
Schwartz rounds, and team meetings dedicated to mutual support.
Conclusions
Future recommendations and developing
the evidence base
A palliative care approach should be introduced early in the care
for patients with HF, focused on optimizing symptom control, and
responsive to dynamic changes in goals of care, during different
phases of the disease trajectory. Concrete proposals and advice
include:
1. Consider palliative care throughout the HF trajectory.
We recommend that all patients with HF should be considered
for palliative care, regardless of stage of their illness. Patients



















































































.. transplantation should receive a palliative care consultation
before such interventions as a matter of protocol. ACP should
be considered for all patients with advanced HF (as outlined in
Figure 1).
2. Addressing needs and preferences for treatment. For
patients with HF, their families or informal caregivers, their
supportive needs and preferences for treatment should be
systematically taken into account, especially in the terminal
phase. Tools and programmes that support patients and fami-
lies engaging in such discussion and decision-making, including
their views on palliative and end of life care, should be devel-
oped and implemented.
3. Optimal symptom control as the focus of care.
Better assessment of palliative care needs supported by
evidence-based validated PROMs is advised. Healthcare
providers need to appreciate the importance of palliative
care, and this should be highlighted and incorporated more
definitively in the specialist HFA training curricula for both
cardiologists and nurses.
4. Specialist palliative care and a palliative care approach
by all professionals. Both should be considered within HF
management, the latter predominately addressing symptom
alleviation, ensuring treatment modalities are aligned with
preferences for care, offering psychosocial support, and fos-
tering care coordination. With regard to integration of a
specialist palliative care MDT model, this requires a degree
of operational flexibility to accommodate local variation in
healthcare structures, available resources, and the spectrum
of professional competences. We recommend that HF pallia-
tive care be the subject of further primary research, alongside
future surveys, registries, and quality assurance initiatives on a
pan-European basis.
5. Preferences for treatment and care of patients, their
families and caregivers. These need to be taken into
account and addressed more systematically throughout all
stages of HF, but especially in the terminal phase. Tools
and programmes that assist patients and families undertaking
difficult discussions, and supporting shared decision-making on
treatment options should be developed and implemented.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Tools to identify the need for a palliative approach.
Table S2. Heart failure phases and exercise prescription.
Table S3. Basic considerations for patient and informal caregiver
teaching.
Table S4. Checklist outlining principles for a ‘good death’.
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